肝细胞肝癌与肝移植(英文)

Hepatocellular carcinoma (HCC) & liver transplantation (LT)

肝细胞癌(HCC)是最常见的肝脏原发性恶性肿瘤。肝移植治疗肝细胞癌(HCC)对合并肝硬化患者是根治性的治疗,包括肿瘤和相关的癌前状态,尤其是肝癌的发展源于慢性肝病的基础上的患者。器官移植供体的短缺已导致等待时间延长,由于肿瘤的进展,从排队序列中被剔除风险增加。新辅助治疗,肝动脉化疗栓塞(TACE),射频消融(RFA)、经皮无水乙醇注射(PEI)作为过渡治疗控制肿瘤的生长。尽管选择标准的扩展是必要的,但它应该建立在良好设计的前瞻性研究的评估之上。本研究展现了德国包括单中心(汉诺威医学院)在肝细胞癌肝移植方面的经验,合理使用肝移植更有利于人类。

Hepatocellular carcinoma( HCC) is the most common primary malignancy of the liver. Liver transplantation for hepatocellular carcinoma( HCC) in patients with cirrhosis is a radical treatment of the tumor and associated precancerous state,especially for HCC developing within an established background of chronic liver disease. Shortage of organ donors has resulted in overall increase of waiting list time with increased risk of dropout due to tumor progression. Neoadjuvant therapies,transarterial chemoembolization( TACE),radiofrequency ablation( RFA) and percutaneous ethanol injection( PEI) have emerged as bridging therapy to control tumor growth. Although expansion of selection criteria is necessary,it should be assessed in the setting of prospective well-designed studies. This research presents German experience including single-center( medical school of Hannover) of undergoing transplantation for HCC. Rational use of liver transplantation is more beneficial for humanbeing.